Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
about
The substantia nigra conveys target-dependent excitatory and inhibitory outputs from the basal ganglia to the thalamus.Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson diseaseIdentification of a subunit-specific antagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate/kainate receptor channels.A single amino acid determines the subunit-specific spider toxin block of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor channels.Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbersGlutamate receptors as therapeutic targets for Parkinson's disease.Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.Therapeutic potential of targeting glutamate receptors in Parkinson's disease.Advances in non-dopaminergic treatments for Parkinson's diseaseMetabotropic glutamate receptors for Parkinson's disease therapy.LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats.The effects of the β-lactam antibiotic, ceftriaxone, on forepaw stepping and L-DOPA-induced dyskinesia in a rodent model of Parkinson's disease.The non-NMDA glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione and 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline, but not NMDA antagonists, block the intrastriatal neurotoxic effect of MPP+.Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia.Deconstructing behavioral neuropharmacology with cellular specificity.Glutamatergic Tuning of Hyperactive Striatal Projection Neurons Controls the Motor Response to Dopamine Replacement in Parkinsonian Primates.
P2860
Q33707910-0B137015-3CEA-49DA-8DD2-9286AEE35F39Q35991189-E70C92DC-3AB7-4CE6-8F90-613E55FFF766Q36063415-0942C6D5-7CF5-467A-AD8A-C75DD6A78210Q36417671-F4A85C3D-738A-410A-AED1-8DD3FCD96B2CQ36799584-B6A7703A-C928-4963-A72D-3182B050D91DQ37585401-0D544443-05C6-4D4E-AA45-32E671EF5ACEQ38056852-FEDBBBEE-09DF-4714-B445-5551E38A0AE4Q38190016-902B2C72-C833-4153-A238-6F61F2E097B6Q38218083-2D766266-96A1-4AFE-9096-68E186D5247AQ41818450-676BA269-0EA7-47AF-8B89-E07B73E7A40DQ43773506-56E0F16C-BD83-4D8B-B472-F406756A8F14Q46332293-DF046B51-A636-4F2C-A1E3-49EB10531CF9Q48148951-780CD996-AE3A-41B5-9506-623552B6F037Q48174974-7C93A225-CD55-41B5-B4F1-A85A48D1053EQ48309715-C27A0FFC-DCCD-4278-9E40-0FA4EC7F1246Q49246060-4957EE28-679A-4972-AB5A-ED823F950252
P2860
Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
Synergism of the AMPA-antagoni ...... models of Parkinson's disease.
@en
Synergism of the AMPA-antagoni ...... models of Parkinson's disease.
@nl
type
label
Synergism of the AMPA-antagoni ...... models of Parkinson's disease.
@en
Synergism of the AMPA-antagoni ...... models of Parkinson's disease.
@nl
prefLabel
Synergism of the AMPA-antagoni ...... models of Parkinson's disease.
@en
Synergism of the AMPA-antagoni ...... models of Parkinson's disease.
@nl
P2093
P356
P1476
Synergism of the AMPA-antagoni ...... models of Parkinson's disease.
@en
P2093
K J Rettig
P A Löschmann
P2888
P304
P356
10.1007/BF02259538
P577
1991-01-01T00:00:00Z